You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
AstraZeneca
Harvard Business School
McKinsey
Merck

Last Updated: December 5, 2020

DrugPatentWatch Database Preview

Patent: 7,582,618

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,582,618
Title:2\'-C-methyl-3\'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
Abstract: The 3\'-L-valine ester of .beta.-D-2\'-C-methyl-ribofuranosyl cytidine provides superior results against flaviviruses and pestiviruses, including hepatitis C virus. Based on this discovery, compounds, compositions, methods and uses are provided for the treatment of flaviviridae, including HCV, that include the administration of an effective amount of val-mCyd or its salt, ester, prodrug or derivative, optionally in a pharmaceutically acceptable carrier. In an alternative embodiment, val-mCyd is used to treat any virus that replicates through an RNA-dependent RNA polymerase.
Inventor(s): Sommadossi; Jean-Pierre (Cambridge, MA), LaColla; Paolo (Capoterra, IT), Gosselin; Gilles (Montpellier, FR)
Assignee: Idenix Pharmaceuticals, Inc. (Cambridge, MA) University of Cagliari (Cagliari, IT) Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpellier II (Montpellier, FR)
Application Number:11/516,928
Patent Claims:see list of patent claims

Details for Patent 7,582,618

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Vidara Therapeutics Research Ltd ACTIMMUNE interferon gamma-1b VIAL; SINGLE-USE 103836 001 1999-02-25   Start Trial Idenix Pharmaceuticals, Inc. (Cambridge, MA) University of Cagliari (Cagliari, IT) Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpellier II (Montpellier, FR) 2022-06-28 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 002 2002-03-07   Start Trial Idenix Pharmaceuticals, Inc. (Cambridge, MA) University of Cagliari (Cagliari, IT) Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpellier II (Montpellier, FR) 2022-06-28 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 001 2002-03-07   Start Trial Idenix Pharmaceuticals, Inc. (Cambridge, MA) University of Cagliari (Cagliari, IT) Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpellier II (Montpellier, FR) 2022-06-28 RX search
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17   Start Trial Idenix Pharmaceuticals, Inc. (Cambridge, MA) University of Cagliari (Cagliari, IT) Centre National de la Recherche Scientifique (Paris, FR) L\'Universite Montpellier II (Montpellier, FR) 2022-06-28 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 7,582,618

Country Patent Number Estimated Expiration
South Africa 200410249   Start Trial
South Africa 200410290   Start Trial
South Africa 200504954   Start Trial
World Intellectual Property Organization (WIPO) 2004002422   Start Trial
World Intellectual Property Organization (WIPO) 2004002999   Start Trial
World Intellectual Property Organization (WIPO) 2004003000   Start Trial
World Intellectual Property Organization (WIPO) 2004052899   Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Harvard Business School
AstraZeneca
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.